13th International Cancer and Medical Oncology Conference and Exhibition Track 7: Hormone Therapy
13th International Cancer and Medical Oncology Conference and Exhibition
Track 7: Hormone Therapy
February 1–2, 2027 | Novotel Al Barsha Dubai, UAE
The rapid evolution of endocrine oncology is transforming the future of cancer treatment, offering more personalized, targeted, and effective therapeutic strategies for hormone-sensitive malignancies. At the forefront of these developments, the 13th International Cancer and Medical Oncology Conference and Exhibition will spotlight Track 7: Hormone Therapy, a specialized scientific session dedicated to the latest breakthroughs in hormonal and endocrine-based cancer therapeutics.
Hosted on February 1–2, 2027, at the prestigious Novotel Al Barsha Dubai, this international oncology gathering will unite leading oncologists, cancer researchers, endocrinologists, pharmaceutical innovators, healthcare professionals, and academic experts to explore emerging advancements shaping modern cancer management.
Advancing the Future of Endocrine Oncology
Hormone therapy remains a cornerstone in the treatment of several hormone-dependent cancers, including breast, prostate, ovarian, and endometrial malignancies. With continuous innovations in biomarker research, targeted endocrine agents, and precision medicine, hormone-based cancer therapies are achieving improved survival outcomes while minimizing treatment-related toxicity.
Track 7 will provide an in-depth scientific platform for discussing:
This dedicated track is designed to encourage multidisciplinary collaboration while advancing evidence-based clinical practice in oncology.
Why Hormone Therapy Continues to Shape Modern Cancer Care
Hormonal therapies have revolutionized the management of hormone-sensitive cancers by enabling long-term disease control, reducing recurrence risks, and improving patient outcomes. As oncology increasingly moves toward personalized medicine, endocrine therapy plays a crucial role in tailoring treatments based on individual tumor biology and receptor expression.
The conference discussions will emphasize how modern hormonal therapies are contributing to:
Experts attending this track will gain valuable insights into both current clinical practices and future therapeutic directions.
Key Scientific Focus Areas
Breast Cancer and Endocrine Therapy
Exploration of estrogen receptor-positive breast cancer management, aromatase inhibitors, selective estrogen receptor degraders (SERDs), and adjuvant endocrine therapies.
Prostate Cancer Hormonal Management
Advances in androgen deprivation therapy (ADT), castration-resistant prostate cancer strategies, and next-generation anti-androgen agents.
Resistance Mechanisms in Hormone Therapy
Understanding acquired resistance pathways and identifying novel molecular targets for overcoming endocrine resistance.
Precision Oncology and Biomarkers
Utilization of genomic profiling and predictive biomarkers to optimize endocrine treatment selection.
Combination Therapeutic Approaches
Integration of hormone therapy with immunotherapy, chemotherapy, radiotherapy, and targeted molecular therapies.
Survivorship and Long-Term Care
Managing endocrine-related adverse effects while improving survivorship outcomes and patient quality of life.
Benefits of Participating in Track 7
International Scientific Exposure
Engage with globally recognized oncology experts, researchers, and healthcare leaders shaping the future of endocrine oncology.
Access to Emerging Research
Discover cutting-edge clinical studies, novel endocrine agents, and breakthrough therapeutic technologies.
Professional Networking Opportunities
Build collaborations with clinicians, pharmaceutical professionals, academic institutions, and healthcare organizations worldwide.
Academic and Career Advancement
Present scientific abstracts, participate in panel discussions, and expand international research visibility.
CME/CPD Accreditation
Participants will receive access to approximately 30 CME/CPD Credits, supporting continuous medical education and professional development.
About the Conference
The 13th International Cancer and Medical Oncology Conference and Exhibition is recognized as a premier global platform for advancing oncology research, clinical excellence, and healthcare innovation. The conference is committed to fostering scientific exchange among multidisciplinary cancer care professionals from around the world.
The event will feature:
This international gathering aims to strengthen global partnerships and accelerate innovation in cancer diagnosis, treatment, and prevention.
About the Venue – Novotel Al Barsha Dubai
Located in the heart of Dubai on Sheikh Zayed Road, Novotel Al Barsha Dubai offers a sophisticated environment for international scientific meetings and medical conferences. The venue combines modern conference infrastructure with world-class hospitality and convenient access to major landmarks, business districts, and transportation networks.
Dubai’s global reputation for healthcare innovation, advanced infrastructure, and international connectivity makes it an exceptional destination for a world-class oncology congress.
Importance of CME/CPD Accreditation
Continuing Medical Education (CME) and Continuing Professional Development (CPD) remain essential for maintaining excellence in healthcare delivery. Through participation in this conference, attendees can enhance their clinical competencies, remain updated with evolving oncology standards, and strengthen evidence-based practice approaches.
CME/CPD Benefits Include:
International academic recognition
Improved patient-care outcomes
Lifelong learning advancement
Who Should Attend?
This track is highly valuable for:
Abstract Submission and Participation Opportunities
The conference welcomes scientific contributions in the form of:
Researchers and healthcare professionals are encouraged to submit abstracts showcasing innovative findings and clinical advancements in endocrine oncology.
Conclusion
Track 7: Hormone Therapy at the 13th International Cancer and Medical Oncology Conference and Exhibition represents a vital scientific platform dedicated to advancing endocrine-based cancer therapeutics and precision oncology. As hormonal treatment strategies continue to evolve, this track will provide exceptional opportunities for knowledge exchange, professional collaboration, and clinical advancement.
By bringing together internationally renowned experts, researchers, and healthcare innovators in Dubai, the conference will contribute significantly to the future of personalized cancer care and endocrine oncology research worldwide.
Important Links
https://cancer.utilitarianconferences.com/
https://cancer.utilitarianconferences.com/registration
https://cancer.utilitarianconferences.com/submit-abstract
.jpg)
.png)
Comments
Post a Comment